Business Context and Reporting Period
Company: Lexicon Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 3, 2025
Event: Notice of potential delisting from The Nasdaq Global Select Market due to failure to maintain the minimum bid price requirement.
Key Financial Metrics
This filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock listing compliance.
Material Changes
Stock Price Deficiency: The company's common stock closing bid price remained below $1.00 per share for the last 31 consecutive business days prior to January 3, 2025, violating Nasdaq Listing Rule 5450(a)(1).
Compliance Status: The company has received a formal Notice from Nasdaq indicating non-compliance but has not been immediately delisted.
Outlook, Management Commentary, and Risks
- Compliance Period: The company has been granted 180 calendar days (until July 2, 2025) to regain compliance.
- Remediation Requirement: To comply, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within the 180-day window.
- Future Options: If compliance is not achieved, the company may seek an additional 180-day period if it meets other listing standards, potentially by effecting a reverse stock split subject to stockholder approval.
- Risks: There is no assurance the company will regain compliance. Failure to cure the deficiency could result in delisting from the Nasdaq Global Select Market.
Investor Verification Checklist
- Verify the current closing bid price of LXRX common stock to assess proximity to the $1.00 threshold.
- Monitor upcoming stockholder meetings for proposals regarding a reverse stock split.
- Review subsequent 8-K filings for updates on compliance status or potential delisting notices.
- Check the company's cash position in recent 10-Q or 10-K filings to evaluate its ability to fund operations if delisting impacts liquidity.